Living Cell Technologies Limited

Company Announcement

Living Cell Technologies Granted European Patent for Neurological Disease Product NTCELL

- NTCELL targets neurological diseases such as Parkinson's disease, Alzheimer's disease, Multiple Sclerosis and Huntington's disease and Stroke
- Patent based on technology of implanting encapsulated porcine choroid plexus cells
- Journal of Neural Engineering publishes LCT's latest data on therapeutic benefit of choroid plexus cell implants

20 January 2010: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that it has been granted a European patent for the use of its product NTCELL in the treatment of degenerative neurological conditions such as Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), Huntington's disease and Stroke.

LCT's European patent is based on the technology of preparing NTCELL, which are encapsulated porcine cells of the choroid plexus of the brain. The cells release growth factors and neurotrophins, which are a range of agents that protect and maintain the health of brain cells. NTCELL was designed to protect brain cells from disease and injury and to enhance the natural repair mechanisms in the brain. NTCELL has the potential to restore neural cells and tissue.

The porcine choroid plexus cells are encapsulated in a seaweed-derived gel. The encapsulation protects the cells from rejection by the immune system allowing implantation without the need for toxic anti-rejection drugs.

Dr Paul Tan, Chief Executive Officer LCT said: "At a time when we are seeing regulatory approvals in Europe and the US for clinical trials with cell-based therapeutics in neurologic disorders, we can expect NTCELL to add significant value to LCT. The granting of this key patent for NTCELL coincides with the publication of LCT's most recent data on cell therapy for neurological diseases in a leading peer review journal."

The December 2009 issue of the Journal of Neural Engineering published LCT's paper titled "*Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma*", which shows that long-lasting therapeutic implants of NTCELL may be used to treat brain disease. The new experimental data indicates that the choroid plexus cells release neuroprotective agents including antioxidants and growth supporting factors. The implanted cells were still alive when retrieved 6 months after implantation into the brain in animals. This publication adds to LCT's previously published and presented data on the beneficial effects of NTCELL implants in animal models of Parkinson's disease, Huntington's disease, stroke and hearing loss caused by degeneration of the auditory nerve.

-Ends-

Reference: Skinner SJM, Geaney MS, Lin H, Muzina M, Anal AK, Elliott RB, Tan PLJ. Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma. J Neural Eng. 6: 1-11, 2009.

Link to abstract of publication: iop.org/EJ/abstract/1741-2552/6/6/065001/





Photos show the choroid plexus of the brain and encapsulated choroid plexus cells.

For further information: www.lctglobal.com

Dr. Paul Tan
Chief Executive Officer
Mob: 021 608 784 (NZ)
Tel:+64 9 276 2690
ptan@lctglobal.com

Prof. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel:+64 9 276 2690
belliott@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690
jcowan@lctglobal.com

Paul Dekkers
Investor and Media Relations
Tel: +612 9237 2800
pdekkers@bcg.com.au

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on

track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.